Richard J. Ablin
Corporate Officer/Principal bij Tetragenex Pharmaceuticals, Inc.
Profiel
Richard J.
Ablin is currently the Director of Tetracycline Evaluation at Tetragenex Pharmaceuticals, Inc. He was previously the Director and Research Associate Professor at The State University of New York from 1983 to 1989.
Ablin received his doctorate degree from the State University of New York at Buffalo in 1967.
Actieve functies van Richard J. Ablin
Bedrijven | Functie | Begin |
---|---|---|
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | Corporate Officer/Principal | 05-02-2010 |
Eerdere bekende functies van Richard J. Ablin
Bedrijven | Functie | Einde |
---|---|---|
The State University of New York | Directeur/Bestuurslid | 01-01-1989 |
Opleiding van Richard J. Ablin
State University of New York at Buffalo | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | Health Technology |